Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page 7 s! [( V1 s; q. a4 n: d7 A$ e
1 }# _; h% Y7 f2 G) ]
8 M. R! K9 Z: D$ \* N9 f SSub-category:
& z( S- s# d9 aMolecular Targets
6 o/ l$ {: {2 c
" f; a0 L! J; \3 y9 V6 }% d- L# q( L, [* {# e: @
Category:7 v o( \( V: g$ w
Tumor Biology
# L! r& Y* R1 n4 |6 ]7 B! n I
. Z: M" r( O* K5 c; u* \9 c, s* c# H" g( U# l' Q. \# r9 B2 m5 g" _
Meeting:
6 }# a0 j3 a. q! @( [# h S# j2011 ASCO Annual Meeting
' u6 ]( G) K0 W* Y
, P3 t, u4 L8 o6 k ]5 k! Q3 z0 N9 H, ^/ o6 _ s
Session Type and Session Title:
8 l7 m, V5 Q. A' y; z3 k2 c! S2 YPoster Discussion Session, Tumor Biology
! x5 j9 N8 n, F$ m5 m5 }8 f
h3 T; q/ M1 N ]; M6 ^8 L, I9 e' z) U2 g& c7 q1 x
Abstract No:
! p4 K1 F4 }, P( [ R" K, A* g* q10517 , \; A& V- V$ k
: `2 K _9 w# u
7 h9 j7 w n; F: ]8 l- _- K
Citation:
6 J) {* w2 d+ G* l9 o. aJ Clin Oncol 29: 2011 (suppl; abstr 10517) 3 W. U: R- {. r' Z, C9 F
4 G. `+ j3 O \- ?& Z! a$ A! Z& ?4 r% m
Author(s):
. U& @: X Q' QJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China - N# w( A! U- R
% c0 ~6 O) @. K" d. [ z
$ `0 j0 F' U9 s( S. I$ M& u
: h# G" M0 F+ K2 F# ZAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
+ b8 ~ Y7 g* _3 L$ u0 `6 h9 ^" h( r. i
Abstract Disclosures
9 }+ {* o9 w6 t$ u3 h& y X' C7 p: w# \- f3 D
Abstract:
! r! e; q9 b. e% S+ I2 A+ T( p" G+ I) @( A7 N
3 {+ N9 N( A E4 A
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
8 m1 c# w7 P2 E7 e" V) `
- v; q7 k3 t3 I: g' z }! P9 \. Z2 w% X; u. O
|